title: p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas.
abstract: Pulmonary blastomas (PBs) are rare primary malignancies that include adult types: biphasic pulmonary blastoma (BPB) and well-differentiated fetal adenocarcinoma (WDFA); and childhood type: pleuropulmonary blastoma (PPB). Their pathogenesis and relationship to bronchogenic carcinoma (BCA) are controversial. To determine whether or not PB share molecular pathological features with BCA, the authors immunostained three BPB, three WDFA, three PPB, and 80 standard BCA for p53 protein and MDM2 protein, gene products believed to be significant in the pathogenesis of BCA. Paraffin-embedded tissue sections were immunostained with monoclonal antibody to p53 and MDM2 proteins. Strong intranuclear staining in greater than 10% of cells was considered positive. Three (50%) BPB and WDFA stained for p53 and five (83%) for MDM2. None of the PPB stained for p53, and one PPB did not stain for either p53 or MDM2. Five of six adult type PB occurred in smokers, whereas none of the PPB was associated with smoking. Seventy-five (94%) of the BCA stained for MDM2 and 46 (61%) for p53. Immunostaining patterns for p53 and MDM2 in adult types of PB, and not PPB, appear similar to those for BCA. This may suggest that adult type PB, but not childhood PB, have a similar pathogenesis to BCA.
authors.affiliation: Department of Pathology, Baylor College of Medicine, Houston, TX, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Pacinda
authors.forename: S C
authors.initials: SC
authors.lastname: Ledet
authors.forename: M M
authors.initials: MM
authors.lastname: Gondo
authors.forename: C
authors.initials: C
authors.lastname: Langston
authors.forename: R W
authors.initials: RW
authors.lastname: Brown
authors.forename: P A
authors.initials: PA
authors.lastname: Carmona
authors.forename: R B
authors.initials: RB
authors.lastname: Franklin
authors.forename: V L
authors.initials: VL
authors.lastname: Roggli
authors.forename: P T
authors.initials: PT
authors.lastname: Cagle
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000473:pathology; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis; D002283:Carcinoma, Bronchogenic / Q000737:chemistry* / Q000473:pathology; D002675:Child, Preschool; D005260:Female; D005333:Fetus; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D008175:Lung Neoplasms / Q000737:chemistry* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D051736:Proto-Oncogene Proteins c-mdm2; D018202:Pulmonary Blastoma / Q000737:chemistry* / Q000473:pathology; D013194:Staining and Labeling; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2